Today: 26 March 2026
Subscribe
Browse Category

Stock Market 24 February 2026

P&G stock holds near $165 as tariff uncertainty keeps investors defensive

P&G stock holds near $165 as tariff uncertainty keeps investors defensive

Procter & Gamble shares rose 0.2% to $165.50 Tuesday afternoon, holding gains after a 2.73% jump Monday as broader markets fell. The Trump administration is preparing to raise the global tariff rate to 15%, a White House official said, with no timeline given. P&G’s trading volume exceeded its average, and a Form 4 filing showed Chief Legal Officer Susan Street Whaley sold 1,809 shares last week. Investors await Nvidia earnings and tariff details Wednesday.
24 February 2026
·
Corning stock (GLW) jumps again as AI data-center cable demand keeps the rally moving

Corning stock (GLW) jumps again as AI data-center cable demand keeps the rally moving

Corning shares climbed nearly 4% Tuesday, hitting a new 52-week high of $152.91 before trading at $150.99 in afternoon action. The stock has surged on heavy volume following a $6 billion supply deal with Meta and rising earnings forecasts. Monday’s close marked a second straight session of gains, with volume more than double the 50-day average. Investors await upcoming conference appearances and the next dividend record date.
24 February 2026
····
Oil prices hold near 7‑month highs: US‑Iran talks, tariffs and inventories set the next move

Oil prices hold near 7‑month highs: US‑Iran talks, tariffs and inventories set the next move

Oil prices hovered near seven-month highs Tuesday before slipping, with Brent futures down 25 cents at $71.24 a barrel and WTI off 25 cents to $66.06 by late morning. A $3–$4 per barrel geopolitical risk premium has emerged amid Middle East tensions, new U.S. tariffs, and surging tanker rates. Traders await U.S. inventory data and Thursday’s U.S.-Iran talks in Geneva.
24 February 2026
·
FTSE 100 today: UK shares finish flat as tariff and AI worries hit banks; Convatec jumps

FTSE 100 today: UK shares finish flat as tariff and AI worries hit banks; Convatec jumps

FTSE 100 closed down 0.04% at 10,680.59; FTSE 250 slipped 0.2%. Convatec surged 10.4% after raising its growth target, while Unite Group dropped 14.3% on a weaker student demand outlook. Standard Chartered missed profit estimates despite a 16% gain and a $1.5 billion buyback. Investors watched new U.S. tariffs and Bank of England rate signals.
24 February 2026
····
India stock market today: Nifty, Sensex tumble over 1% as IT rout deepens on AI fears

India stock market today: Nifty, Sensex tumble over 1% as IT rout deepens on AI fears

The Nifty 50 fell 1.1% and the Sensex dropped over 1,000 points Tuesday, led by a 4.7% plunge in IT stocks to a 30-month low. Tata Consultancy Services, Infosys, HCLTech, and Wipro lost up to 6.1% amid AI disruption fears and a Jefferies downgrade. Market capitalization dropped by 3.5 trillion rupees. Textile exporters also declined after export incentive cuts.
24 February 2026
·····
Lumentum stock hits fresh high as traders lean into AI optics demand

Lumentum stock hits fresh high as traders lean into AI optics demand

Lumentum shares hit $688.27 before easing to $674.73, up about 1.1% in late-morning New York trading Tuesday, with volume at 4.5 million shares. The move follows strong demand for optical circuit switches and co-packaged optics tied to AI data centers. Investors await management’s investor briefing at OFC on March 17. Peers traded mixed, while the broader semiconductor ETF slipped 0.7%.
24 February 2026
···
Walmart stock price today: WMT rises as fresh analyst targets land and markets steady

Walmart stock price today: WMT rises as fresh analyst targets land and markets steady

Walmart shares climbed 1.7% to $127.89 Tuesday after Evercore ISI and Barclays raised their price targets. SEC filings showed executive vice presidents Nicholas Christopher James and Latriece Watkins sold shares last week. Investors weighed tariff risks and AI-driven volatility ahead of key earnings. Walmart recently reported $190.7 billion in Q4 revenue and announced a $30 billion buyback.
24 February 2026
·
Palo Alto Networks stock hits a fresh 52-week low — what’s spooking PANW investors now

Palo Alto Networks stock hits a fresh 52-week low — what’s spooking PANW investors now

Palo Alto Networks shares fell 0.5% to $143.39 after hitting a 52-week low Tuesday, underperforming the Nasdaq’s 0.8% gain. The drop followed a sharp selloff in cybersecurity stocks after Anthropic launched a new code-security AI tool. Daiwa Securities cut its price target on Palo Alto to $175 from $212. The company last week reported fiscal Q2 revenue of $2.6 billion and non-GAAP profit of $1.03 per share.
24 February 2026
·
Meta stock slips as AMD AI chip pact puts spending back in focus ahead of Nvidia earnings

Meta stock slips as AMD AI chip pact puts spending back in focus ahead of Nvidia earnings

Meta Platforms shares fell 2.8% to $637.25 after AMD agreed to supply up to $60 billion in AI chips over five years, with Meta gaining an option for up to 10% of AMD’s equity. AMD will begin shipments in late 2026. Nvidia’s earnings report on Feb. 25 is seen as the next key indicator for AI demand and tech sector spending.
24 February 2026
·····
AMD stock price jumps after Meta AI chip deal includes 10% stake option

AMD stock price jumps after Meta AI chip deal includes 10% stake option

AMD shares rose 7% to $210.30 after Meta agreed to buy up to $60 billion in AI chips over five years, with a warrant to purchase up to 160 million AMD shares at $0.01 each. The warrant vests in tranches tied to shipment and stock price milestones, running until February 2031. First shipments are scheduled for the second half of 2026. Traders await Nvidia’s earnings on Feb. 25.
24 February 2026
····
Microsoft stock steadies near $385 as AI spending worries set the tone for MSFT

Microsoft stock steadies near $385 as AI spending worries set the tone for MSFT

Microsoft shares rose 0.2% to $385.28 in early Tuesday trading after a 3.2% drop the previous session. Bridgewater Associates estimated Big Tech could spend $650 billion on AI infrastructure this year, warning of downside risk. Investors are watching Nvidia’s earnings Wednesday for signals on AI demand. Microsoft CEO Satya Nadella is scheduled to speak at a Morgan Stanley conference on March 4.
24 February 2026
········
Micron stock price rises as chip trade steadies ahead of Nvidia earnings

Micron stock price rises as chip trade steadies ahead of Nvidia earnings

Micron shares rose about 1.5% to $427.08 in early Tuesday trading, rebounding after a tariff-driven selloff. Investors focused on AI hardware demand and upcoming Nvidia results, while broader markets stayed flat. AMD announced a $60 billion AI chip deal with Meta, lifting chip sentiment. Tariff uncertainty and supply constraints continued to weigh on the sector.
24 February 2026
······
SanDisk stock steadies after Citron short call; SNDK traders watch next catalysts

SanDisk stock steadies after Citron short call; SNDK traders watch next catalysts

Sandisk shares rose 1.3% to $675.19 Tuesday morning after Citron Research disclosed a short position and warned the NAND chip shortage could end quickly. The stock dipped briefly after Citron’s post before rebounding. Citron cited rising competition, especially from Samsung, as a risk. Investors are watching Sandisk’s conference appearances starting Feb. 25 for updates.
24 February 2026
··
1 … 68 69 70 71 72 … 1,363

Stock Market Today

  • Innate Pharma Shares Slide on 55% Revenue Drop, Cash Runway Risks Ahead of Q1 2026 Results
    March 26, 2026, 9:00 AM EDT. Innate Pharma (IPH.PA) faces a sharp 55% decline in Q4 revenue, casting a shadow over its financial health ahead of Q1 results scheduled for 26 March 2026. The biotech's stock opened under pressure at €1.094, below its 50- and 200-day averages, signaling investor concern. With cash runway extending only to the end of Q3 2026, funding challenges loom as the company burns through cash at the current rate. The loss-making firm reports an EPS of -0.55 and a high debt-to-equity ratio of 5.25, raising questions about near-term liquidity. Key trial results, particularly for Monalizumab and Lacutamab, alongside partnership updates with AstraZeneca and Sanofi, remain critical catalysts. Traders should watch cash visibility, cost control, and management commentary closely to gauge Innate Pharma's path forward amidst sector headwinds and valuation pressures.
Go toTop